Spinocerebellar Ataxia Type 1
13
2
5
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
0.0%
0 terminated out of 13 trials
100.0%
+13.5% vs benchmark
15%
2 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (13)
Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-SA) for Patients With Spinocerebellar Ataxia
Troriluzole in Adult Participants With Spinocerebellar Ataxia
A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Instrumented Data Exchange for Ataxia Study
Open Pilot Trial of BHV-4157
Priming Motor Learning Through Exercise in People With Spinocerebellar Ataxia
Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias
Clinical Trial Readiness for SCA1 and SCA3
Study of CAD-1883 for Spinocerebellar Ataxia
Cerebello-Spinal tDCS as Rehabilitative Intervention in Neurodegenerative Ataxia
Rehabilitative Trial With Cerebello-Spinal tDCS in Neurodegenerative Ataxia
Biomarkers in Autosomal Dominant Cerebellar Ataxia